The success of precision oncology depends heavily on identifying and validating reliable biomarkers. From predicting drug response to monitoring resistance, biomarkers shape treatment strategies and guide clinical decision-making. However, robust biomarker discovery requires access to high-quality, reproducible specimens. This is where the ffpe tissue block<\/strong><\/a> plays a pivotal role.<\/p>\n In our previous article, we introduced the basics and advantages of ffpe tissue samples<\/strong><\/a>. In this part of the series, we explore how FFPE technology accelerates biomarker discovery and validation<\/strong><\/a>, with real-world examples in lung and colorectal cancer research.<\/p>\n Biomarkers are measurable indicators\u2014genetic, protein, or molecular\u2014that provide insights into tumor biology. They are used to:<\/p>\n Predict therapy response<\/strong> (e.g., EGFR mutations<\/a> in NSCLC)<\/p>\n<\/li>\n Determine prognosis<\/strong> (likelihood of recurrence or survival)<\/p>\n<\/li>\n Guide treatment selection<\/strong> (targeted therapies vs immunotherapies)<\/p>\n<\/li>\n Track resistance mechanisms<\/strong><\/p>\n<\/li>\n<\/ul>\n Without validated biomarkers, targeted therapies cannot reach their full potential. FFPE tissue samples for biomarker discovery<\/strong> provide the backbone of these studies by offering preserved tumor material annotated with clinical metadata.<\/p>\n Biomarker discovery requires analyzing patterns across many patients. NSCLC ffpe tissue blocks with EGFR mutations<\/strong><\/a> or CRC FFPE blocks with MLH1, PMS2, MSH2, and MSH6<\/strong><\/a> allow researchers to validate findings in hundreds of cases under consistent conditions.<\/p>\n FFPE tissue samples<\/strong> can be analyzed using a wide range of technologies, such as:<\/p>\n Immunohistochemistry (IHC):<\/strong> Protein expression markers like PD-L1<\/p>\n<\/li>\n PCR and qPCR:<\/strong> Gene mutation detection (e.g., KRAS, BRAF)<\/p>\n<\/li>\n Next-generation sequencing (NGS):<\/strong> Comprehensive mutational profiling<\/p>\n<\/li>\n FISH:<\/strong> Structural rearrangements such as ALK or ROS1 fusions<\/p>\n<\/li>\n<\/ul>\n This versatility makes ffpe tissue blocks<\/strong> uniquely suited for biomarker pipelines.<\/p>\n Since FFPE samples can be stored for decades, researchers can retrospectively correlate biomarker status with long-term survival and treatment outcomes. This is particularly valuable in diseases like breast or colorectal cancer, where archival material informs today\u2019s clinical guidelines.<\/p>\n
\nWhy Biomarkers Matter in Cancer Research<\/h2>\n
\n
\nHow FFPE Tissue Blocks Support Biomarker Research<\/h2>\n
Large Cohorts for Validation<\/h3>\n
Compatibility with Multiple Testing Platforms<\/h3>\n
\n
Retrospective Studies with Clinical Outcomes<\/h3>\n
\nCase Studies in Biomarker Validation<\/h2>\n
EGFR in Non-Small Cell Lung Cancer<\/a> (NSCLC)<\/h3>\n